BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 2814910)

  • 1. [Prevention of recurrence of thromboembolic disease: maintenance of anticoagulant therapy].
    Enrico JF
    Ther Umsch; 1989 Oct; 46(10):732-8. PubMed ID: 2814910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
    N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Duration of antivitamin K therapy in venous thromboembolic disease].
    Ferrari E; Baudouy M; Morand P
    Arch Mal Coeur Vaiss; 1995 Dec; 88(12):1891-4. PubMed ID: 8729371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term management of patients after venous thromboembolism.
    Kearon C
    Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
    Prandoni P; Simioni P; Pagnan A
    Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of venous thrombosis in cancer patients: practical aspects].
    Laza-Achille M; Desruennes E; Di Palma M
    Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Strategies for utilization of anticoagulants in pulmonary embolism].
    Fartoukh M; Simonneau G
    Rev Mal Respir; 1999 Nov; 16(5 Pt 2):949-60. PubMed ID: 10907444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DVT and pulmonary embolism: Part II. Treatment and prevention.
    Ramzi DW; Leeper KV
    Am Fam Physician; 2004 Jun; 69(12):2841-8. PubMed ID: 15222649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant treatment of venous thromboembolism.
    Coon WW
    Surg Annu; 1972; 4():151-63. PubMed ID: 4668856
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy of deep vein thrombosis.
    Turpie AG
    Herz; 1989 Dec; 14(6):341-7. PubMed ID: 2695442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
    Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
    Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of acute symptomatic deep vein thrombosis.
    Heit JA
    Am J Cardiovasc Drugs; 2001; 1(1):45-50. PubMed ID: 14728051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin and warfarin: use of anticoagulants in the prevention and treatment of venous thrombosis and pulmonary embolism.
    Rosen RL
    J Fam Pract; 1979 May; 8(5):923-7. PubMed ID: 438753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of thromboembolic complications with adapted low-dose of antivitamins K after total hip prosthesis].
    Hernigou P; Février MJ; Kergrohen F
    Rev Chir Orthop Reparatrice Appar Mot; 1993; 79(7):577-85. PubMed ID: 8085039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J; Kiesewetter H; Jörg I; Harenberg J
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Duration of antivitamin K therapy in venous thromboembolic disease. Certainties and uncertainties].
    Ferrari E; Schiano N; Benhamou M; Baudouy M
    Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1301-6. PubMed ID: 11794973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
    Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
    Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended treatment for venous thromboembolism: how long is long enough?
    Cosmi B; Palareti G
    Curr Hematol Rep; 2004 Sep; 3(5):375-81. PubMed ID: 15341706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.